Related references
Note: Only part of the references are listed.Ethnic Differences in Pharmacokinetics in New Drug Applications and Approved Doses in Japan
Satoshi Fukunaga et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Effective Global Drug Development Strategy for Obtaining Regulatory Approval in Japan in the Context of Ethnicity-Related Drug Response Factors
K. Ichimaru et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies
S. U. Yasuda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, 1498 a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects
Susan E. Shoaf et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Predicting effect of food on extent of drug absorption based on physicochemical properties
Chong-Hui Gu et al.
PHARMACEUTICAL RESEARCH (2007)
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia
Robert W. Schrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ethnic or racial differences revisited - Impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics
Mei-Ling Chen
CLINICAL PHARMACOKINETICS (2006)
Differences in drug pharmacokinetics between east Asians and Caucasians and the role of genetic polymorphisms
K Kim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Share Paper
